No Data
No Data
Global Pulmonary Drugs Market Is Expected to Showcase a Significant Growth by 2030, Predicts DelveInsight | Key Companies - F. Hoffmann-La Roche, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Sanofi, Grifols, Regeneron
New York, USA, April 25, 2024 (GLOBE NEWSWIRE) -- Global Pulmonary Drugs Market is Expected to Showcase a Significant Growth by 2030, Predicts DelveInsight | Key Companies - F. Hoffmann-La Roche, AstraZeneca,
GlaxoSmithKline sues Pfizer and BioNTech over mRNA vaccine technology
GLONGHUI, April 25 | GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing on the company's patents relating to RNA (mRNA) technology. GlaxoSmithKline claims Pfizer's and BioNTech's ComirNaty vaccine infringes on the company's patent for an mRNA vaccine innovation developed “more than a decade before the COVID-19 pandemic broke out.” A Pfizer spokesperson said in a statement that they are confident of our intellectual property position in Comirnaty and intend to make a “strong defense” against GlaxoSmithKline's claim.
CureVac Begins Early Stage Portion of Investigational Vaccine Trial
CureVac (CVAC) said Wednesday it initiated the early stage portion of a broader study into an investigational flu vaccine developed with GSK (GSK). The phase 1 trial is part of a combined phase 1/2 st
CureVac Has Started The Phase 1 Part Of A Combined Phase 1/2 Study Of An Investigational Influenza A (H5N1) Pre-Pandemic Vaccine Candidate Developed In Collaboration With GSK, H5N1 Is An Avian Influenza Virus
CureVac Has Started The Phase 1 Part Of A Combined Phase 1/2 Study Of An Investigational Influenza A (H5N1) Pre-Pandemic Vaccine Candidate Developed In Collaboration With GSK, H5N1 Is An Avian Influen
CureVac And GSK Will End The Pandemic Preparedness Agreement Jointly Concluded With The Federal Republic Of Germany In April 2022, After Consultation With The German Federal Ministry Of Health
CureVac And GSK Will End The Pandemic Preparedness Agreement Jointly Concluded With The Federal Republic Of Germany In April 2022, After Consultation With The German Federal Ministry Of Health
The FDA Has Accepted Supplemental Biologics License Application For GSK's Jemperli (Dostarlimab) In Combination With Standard-of-care Chemotherapy To Expand Treatment To All Adult Patients With Primary Advanced Or Recurrent Endometrial Cancer
The FDA Has Accepted Supplemental Biologics License Application For GSK's Jemperli (Dostarlimab) In Combination With Standard-of-care Chemotherapy To Expand Treatment To All Adult Patients With Primar
No Data